Shh-SURF4 Interaction Blocking for Ligand-Dependent Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Hh pathway inhibitors targeting components downstream of Hh ligand reception, such as SMO and Gli, fail to show efficacy in ligand-dependent cancer types, highlighting the need to target Shh signaling directly to inhibit cancer progression.
Innovation Solution
Blocking the interaction between Sonic hedgehog (Shh) and Surfeit locus protein 4 (SURF4) by mutating specific residues or using polypeptides and small chemical molecules, such as glycosaminoglycans, to inhibit Shh secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current Hh pathway inhibitors targeting downstream components (SMO and Gli) are used, then cancer progression is inhibited in some cases, but they fail to show efficacy in ligand-dependent cancer types
Solution Approach 1:
The invention extracts and targets the specific Shh-SURF4 interaction mechanism upstream of the Hh pathway. By focusing on the ligand secretion step mediated by SURF4, the treatment addresses the root cause of ligand-dependent cancer progression rather than downstream effects, thereby improving efficacy in this specific cancer subtype while maintaining a targeted approach.
Solution Approach 2:
Instead of inhibiting downstream components (SMO, Gli) as conventional treatments do, the invention inverts the approach by targeting the upstream ligand secretion step. This reversal allows the treatment to effectively address ligand-dependent cancers by preventing Shh from reaching its receptor in the first place, rather than blocking downstream signaling.
2Reliability
If Shh secretion is inhibited by blocking Shh-SURF4 interaction, then ligand-dependent cancers are effectively targeted, but the molecular mechanisms of Shh secretion remain unclear
Solution Approach 1:
The invention performs preliminary identification of SURF4 as the cargo receptor mediating Shh secretion from producing cells. By establishing this mechanism upfront through mutational analysis and functional studies, the invention creates a foundation for developing targeted inhibitors while simultaneously filling the knowledge gap about Shh secretion mechanisms.
Solution Approach 2:
The invention identifies SURF4 as an intermediary cargo receptor that mediates the secretion of Shh from producing cells. By characterizing this intermediary component and its interaction with Shh, the invention both explains the secretion mechanism and provides a specific target for therapeutic intervention in ligand-dependent cancers.
3Reliability
If mutations in SURF4 residues (E50, D53, D56) or Shh CW motif are introduced to block interaction, then Shh secretion is inhibited, but the complexity of identifying and validating specific interaction sites increases
Solution Approach 1:
The invention segments the Shh-SURF4 interaction into specific identifiable regions: the CW motif (amino acid residues 32-38) on Shh and residues E50, D53, D56 on SURF4. By dividing the interaction interface into these discrete segments, the invention simplifies the identification and targeting of the interaction sites while maintaining high specificity for blocking Shh secretion.
Solution Approach 2:
The invention focuses on specific local regions (the CW motif on Shh and adjacent residues on SURF4) rather than attempting to modify the entire proteins. This localized approach to identifying and mutating interaction sites reduces complexity by concentrating efforts on critical functional regions that mediate the Shh-SURF4 binding.
Data Source
AI summary
Provided are compositions and methods that block the interaction between Sonic hedgehog (Shh) and Surfeit locus protein 4 (SURF4), particularly for use in treating subjects with cancer or at risk of suffering from cancer. The subject methods block the interaction between SURF4 and Shh, either by mutating residue E50, D53, D56, or any combination thereof of SURF4 or mutating the CW motif (amino acid residues 32-38) on human Shh. Also provided is a composition comprising a polypeptide that contains the CW motif at the position of 32-38 on human Shh, a polypeptide that contains the first luminal loop (residues 49-60) of human SURF4, or small chemical molecules that block the interaction between SURF4 and Shh and administering said composition to a subject, particularly in subjects with cancer or at risk of suffering from cancer.